Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.

MLA

Bagnasco, Diego, et al. “Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.” Biomedicines, vol. 11, no. 9, Aug. 2023. EBSCOhost, https://doi.org/10.3390/biomedicines11092424.

APA

Bagnasco, D., Nicola, S., Testino, E., Brussino, L., Pini, L., Caminati, M., Piccardo, F., Canevari, R. F., Melissari, L., Ioppi, A., Guastini, L., Lombardi, C., Milanese, M., Losa, F., Robbiano, M., De Ferrari, L., Riccio, A. M., Guida, G., Bonavia, M., … On Behalf Of Sani. (2023). Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders. Biomedicines, 11(9). https://doi.org/10.3390/biomedicines11092424

Chicago

Bagnasco, Diego, Stefania Nicola, Elisa Testino, Luisa Brussino, Laura Pini, Marco Caminati, Federica Piccardo, et al. 2023. “Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders.” Biomedicines 11 (9). doi:10.3390/biomedicines11092424.